World-renowned addiction doctor talks about combating alcohol and opioid addiction during National Alcohol Awareness Month
CHARLOTTESVILLE, VA / ACCESSWIRE / April 22, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that its Chief Medical Officer, Bankole Johnson, MD, a recent recipient of the American Society of Addiction Medicine’s highest honor, was featured on WPTV-TV, the NBC affiliate in West Palm Beach, Florida.
Dr. Johnson discussed the fight against alcohol use disorder (AUD), opioid addiction and the addiction epidemic. As Chief Medical Officer of Adial Pharmaceuticals, Dr. Johnson is supporting the advancement of Adial’s anticipated Phase 3 trial of its lead investigational drug, AD04, as a potential treatment for AUD in patients with certain, targeted genetics. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
William Stilley, CEO of Adial Pharmaceuticals, commented, “We are very fortunate that Dr. Johnson has left his esteemed full-time position in academia to join Adial as our Chief Medical Officer. Dr. Johnson is the inventor of the substantial intellectual property underpinning AD04 and led the Phase 2b clinical study of AD04 for AUD at the University of Virginia, which met its end-points. It is only appropriate that WPTV-TV, an NBC affiliate, spoke with Dr. Johnson during this National Alcohol Awareness Month.”
The interview is available at: https://www.wptv.com/about-us/as-seen-on/solutions-to-beating-drug-alcohol-abuse
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (“AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to shortly commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Forward Looking Statements
This communication contains certain ‘forward-looking statements’ within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words ‘believes,’ ‘expects,’ ‘anticipates,’ ‘intends,’ ‘projects,’ ‘estimates,’ ‘plans’ and similar expressions or future or conditional verbs such as ‘will,’ ‘should,’ ‘would,’ ‘may’ and ‘could’ are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding AD04 as a potential treatment for alcohol use disorder (AUD) in patients with certain, targeted genetics, the belief that AD04 has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity and the plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using our proprietary companion diagnostic genetic test. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability commence the Phase 3 clinical trials as planned, the ability of AD04 to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in Annual Report on Form 10-K for the year ended December 31, 2018, and our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Crescendo Communications, LLC
Email: [email protected]
SOURCE: Adial Pharmaceuticals, Inc.
View source version on accesswire.com: